赛诺菲「度普利尤单抗」同日获批两项新适应症

Core Viewpoint - Sanofi's Dupilumab injection (brand name: Dupixent) has received official approval from the National Medical Products Administration (NMPA) for two new indications: treatment of bullous pemphigoid in adult patients and maintenance treatment for asthma in children aged 6 and above, marking significant advancements in treatment options for these patient groups [1][4]. Group 1: Product Approval and Indications - Dupilumab is now the first and only targeted biologic approved in China for the treatment of bullous pemphigoid [1]. - It is also the first and only anti-IL-4Ra monoclonal antibody approved in China for maintenance treatment of asthma in children aged 6 and above [1]. - The drug has been approved for nine indications in China, including moderate to severe atopic dermatitis, nodular prurigo, bullous pemphigoid, asthma, and chronic obstructive pulmonary disease (COPD) [4]. Group 2: Clinical Benefits and Mechanism - Dupilumab is a fully human monoclonal antibody that inhibits the signaling pathways of interleukin-4 (IL-4) and interleukin-13 (IL-13), rather than acting as an immunosuppressant [4]. - Clinical trials have shown significant clinical benefits, demonstrating the drug's ability to suppress type 2 inflammation, which is a key driver in various related common diseases [4]. Group 3: Market Context and Future Outlook - The approval comes at a time when China is experiencing deep population aging, with bullous pemphigoid's incidence closely linked to this demographic shift, impacting the quality of life for elderly patients [5]. - Sanofi aims to address unmet medical needs in China and is committed to accelerating the introduction of transformative innovations to improve patient outcomes [5].